North America Contract Research Organization Services Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 26.95 Bn

Forecast Year, 2035

USD 54.01 Bn

CAGR, 2026 - 2035

7.20%

Report Coverage

North America

The North America contract research organization services market size is calculated at USD 26.95 billion in 2025 and is predicted to gain around USD 54.01 billion by 2035, expanding at a CAGR of 7.20% from 2026 to 2035. The market is mainly driven by R&D in pharmaceuticals and biotechnology spending, the growing complexity of clinical trials, the increasing prevalence of chronic diseases, and a strong trend towards outsourcing drug development to save costs and speed up market entry.

North America Contract Research Organization Services Market Statical Scope

The market is crucial as it acts as the global hub for pharmaceutical and medical research. It facilitates rapid drug development, reducing operational expenses, and managing intricate clinical trials for life-saving treatments. Major biopharmaceutical firms allocate substantial research funds in this region to expedite the development of modern therapies. North America boasts top-notch medical facilities, strong digital health integration, and leading laboratories.

The complex regulations from agencies like the FDA need specialized management, which local CROs handle proficiently. The move towards advanced cell and gene therapies and precision medicine demands tailored, high-tech trial designs. Close collaboration with technology sectors helps in the swift implementation of decentralized and hybrid clinical trial models.

North America Contract Research Organization Services Market, By Service Type, 2025 (%)

• Drug Discovery - The drug discovery segment, with a share of 15.00% in 2025, is crucial in the North America Contract Research Organization (CRO) Services Market as it is the essential starting point for life-saving treatments. It helps large pharmaceutical companies and small biotech firms to reduce high early-stage R&D expenses, utilize specialized artificial intelligence and high-throughput screening technologies, and delegate high-risk target identification and candidate validation to expert external teams.
• Preclinical Studies - The preclinical studies segment, with a share of 13.00% in 2025, is essential in the North America Contract Research Organization (CRO) services market as it lays the necessary groundwork for drug safety, pharmacokinetics, and proof-of-concept testing that regulatory bodies like the FDA require before human clinical trials begin. By outsourcing these initial evaluations, regional biopharma companies lower the costs and take advantage of specialized infrastructure.
• Phase I - The Phase I segment, with a share of 12.00% in 2025, is important in the North America Contract Research Organization (CRO) services market as it represents the crucial first step of testing experimental drugs in humans. It provides early insights into safety, toxicity, and pharmacokinetics, allowing small biotech firms and large pharmaceutical companies to effectively screen candidates before committing significant investments in later-stage trials.

North America Contract Research Organization Services Market, By Application, 2025 (%)

• Oncology - The oncology segment, with a share of 35.00% in 2025, dominates the North American Contract Research Organization (CRO) market, due to the high incidence of cancer, extensive pipelines for targeted therapies and immunotherapies, and the intricate nature of managing specialized, multi-phase oncology clinical trials.
• Cardiology - The cardiology segment, with a share of 18.00% in 2025, is a key component in the North America Contract Research Organization (CRO) services market due to the high prevalence of heart disease in the region, significant spending on pharmaceutical and medical device R&D, and the complex clinical trials that require specialized digital tracking and advanced patient monitoring technologies.

North America Contract Research Organization Services Market, By End User, 2025 (%)

• Pharmaceutical & Biotechnological Companies - The pharmaceutical and biotechnological companies segment, with a share of 68.00% in 2025, accounts for the largest revenue share as these businesses are the main sponsors driving the demand for clinical research. They outsource tasks including discovery, clinical trials, and regulatory processes to reduce high R&D expenses, handle complex biologics, and speed up drug delivery in the competitive North American market.
• Medical Device Companies - The medical device companies segment, with a share of 17.00% in 2025, plays a vital role in the North America contract research organization (CRO) services market by generating a strong demand for specialized clinical trials, navigating strict regulations, and fostering rapid product innovation. By outsourcing, device manufacturers decrease significant in-house R&D costs and speed up their time-to-market.

Competitive Landscape

The North America Contract Research Organization (CRO) services market is very competitive and consolidated, dominated by major global companies that offer tech-enabled clinical trials, decentralized studies, and integrated lab services, fueled by significant biopharmaceutical R&D and advanced pipelines in oncology and rare diseases.

• IQVIA, as the industry leader, uses advanced analytics, healthcare intelligence, and global reach to handle complex late-phase clinical trials and site selections.
• Thermo Fisher Scientific (including PPD) merges core lab analytics, clinical research, and a large CDMO network through its PPD clinical research division, providing comprehensive drug development from discovery to post-approval.
• Charles River Laboratories is recognized as a leader in preclinical and early-phase markets, offering essential research models, discovery support, safety assessments, and analytical services.
• ICON plc, after significant strategic acquisitions, provides full-service global clinical development, site management, decentralized trial solutions, and specialized imaging services.
• Parexel, a top full-service global CRO, focuses on managing Phase I–IV clinical trials, regulatory consulting, and patient-centric recruitment strategies.
• Syneos Health uniquely combines clinical development with commercialization services, ensuring trial execution aligns with market-access strategies.
• Medpace operates with a specialized, scientifically driven approach, focusing on full-service mid-sized clinical development and prioritizing high-quality execution for biotech and pharma sponsors.

Segments Covered in the Report

By Service Type

• Drug Discovery
• Preclinical Studies
• Phase I
• Phase II
• Phase III
• Phase IV
• Others

By Application

• Oncology
• Cardiology
• Infectious Disease
• Metabolic Disorders
• Others

By End User

• Pharmaceutical & Biotechnological Companies
• Medical Device Companies
• Academic & Research Institutes
• Others